良性设计的SAHA类似物用于人类和动物的媒介性寄生虫疾病
Michele Rossi1, Bianca Martinengo1, Eleonora Diamanti1
1Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, Via Belmeloro 6, Bologna 40126, Italy.
ACS medicinal chemistry letters
|September 18, 2024
概括
研究人员使用绿色化学方法,从果仁的液体废物中开发出新型药物类似物. 化合物13对Trypanosoma brucei具有显著的活性,Trypanosoma brucei是一种导致非洲睡眠病的寄生虫,没有观察到毒性.
科学领域:
- 药用化学 医学化学
- 绿色化学 绿色化学
- 寄生虫学的寄生虫学
- 药物发现 药物发现 药物发现
背景情况:
- 迫切需要新的药物与"健康"和"绿色化学"原则保持一致.
- 坚果液 (CNSL) 是一个丰富的农业工业废物来源.
- 苏贝罗伊兰尼利德酸 (SAHA) 是一种已知的药物,但正在寻找更绿色的替代品.
研究的目的:
- 使用可持续方法,从CNSL废物中开发新的SAHA类似物.
- 为了评估合成的化合物对毒性和抗寄生虫活性.
- 研究有希望的抗寄生虫候选药物的作用机制.
主要方法:
- 通过转解方法从CNSL合成SAHA类似物 (化合物13-20).
- 对HepG2,IMR-32和L929细胞系的细胞毒性评估.
- 对主要人类和动物载体传播的寄生虫病 (VBPDs) 的查.
- 在体研究中,化合物13与Trypanosoma brucei HDAC (TbDAC) 结合.
主要成果:
- 化合物13-20的合成效率高,并且在体外没有证明有毒性.
- 化合物13表现出对Trypanosoma brucei的tripomastigote形式的强有力的活性.
- 在分析表明,化合物13与TbDAC的催化口袋结合,类似于SAHA.
结论:
- 来自CNSL的SAHA类似物代表着一种可持续的药物发现方法.
- 化合物13是治疗非洲睡眠病的有希望的绿色打击.
- 这项研究为从农业垃圾中开发新的抗寄生虫剂提供了基础.
更多相关视频
11:28Analysis of Iophenoxic Acid Analogues in Small Indian Mongoose Herpestes Auropunctatus Sera for Use as an Oral Rabies Vaccination Biological Marker
Published on: May 31, 2019
5.8K
08:20Author Spotlight: AI-Driven Trypanosome Species Detection from Microscopic Images
Published on: October 27, 2023
1.4K
相关概念视频
Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
American Trypanosomiasis
Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
